Mitochondrial dysfunction and oxidative stress in Alzheimer’s disease, and Parkinson’s disease, Huntington’s disease and Amyotrophic Lateral Sclerosis -An updated review

Mitochondrion, Journal Year: 2023, Volume and Issue: 71, P. 83 - 92

Published: June 1, 2023

Language: Английский

---

Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers

Neurotherapeutics, Journal Year: 2022, Volume and Issue: 19(1), P. 209 - 227

Published: Jan. 1, 2022

Scientific advances over the last four decades have steadily infused Alzheimer's disease (AD) field with great optimism that therapies targeting Aβ, amyloid, tau, and innate immune activation states in brain would provide modification. Unfortunately, this optimistic scenario has not yet played out. Though a recent approval of anti-Aβ aggregate binding antibody, Aduhelm (aducanumab), as "disease-modifying therapy for AD" is viewed by some breakthrough, many remain unconvinced data underlying approval. Collectively, we succeeded changing AD from largely untreatable, inevitable, incurable to treatable, preventable, curable one. Here, I will review major foci "disease-modifying" therapeutic pipeline "open questions" terms these approaches. conclude discussing how we, field, might adjust our approach, learning past failures ensure future success.

Language: Английский

---

Conformational strains of pathogenic amyloid proteins in neurodegenerative diseases

Nature reviews. Neuroscience, Journal Year: 2022, Volume and Issue: 23(9), P. 523 - 534

Published: May 30, 2022

Language: Английский

---

Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease

Acta Neuropathologica Communications, Journal Year: 2022, Volume and Issue: 10(1)

Published: June 22, 2022

Currently, there is a need for diagnostic markers in Lewy body disorders (LBD). α-synuclein (αSyn) RT-QuIC has emerged as promising assay to detect misfolded αSyn clinically or neuropathologically established patients with various synucleinopathies. In this study, was used analyze lumbar CSF clinical cohort from the Swedish BioFINDER study and postmortem ventricular neuropathological Arizona Study of Aging Neurodegenerative Disorders/Brain Body Donation Program (AZSAND/BBDP). The included 64 PD/PDD, 15 MSA, PSP, 47 controls two who later converted PD/DLB. 101 cases different brain disorders, including LBD controls. identified (i.e. PD, PDD converters) vs. sensitivity 95% specificity 83%. that were positive. Within AZSAND/BBDP cohort, verified "standard LBD" PD AD DLB; n = 25) no LB pathology (n 53) high (100%) (94%). Only 57% positive subgroup "non-standard" (i.e., Bodies not meeting criteria DLB incidental LBD, 23). Furthermore, reliably cortex (97% sensitivity) LBs present only olfactory bulb (93% specificity). However, low, 50%, restricted brainstem amygdala, affecting allocortex neocortex. conclusion, samples highly sensitive specific identifying clinicopathologically-defined shows lower non-standard asymptomatic modest cortex.

Language: Английский

---

Connectome-based modelling of neurodegenerative diseases: towards precision medicine and mechanistic insight

Nature reviews. Neuroscience, Journal Year: 2023, Volume and Issue: 24(10), P. 620 - 639

Published: Aug. 24, 2023

Language: Английский

---